What is the current market size?

The Glaucoma Aqueous Shunt market size reached USD 1.1 billion in 2023, driven by rising glaucoma prevalence and surgical adoption in developed regions.

What is the expected growth rate?

The market is projected to grow at a CAGR of 6.2% from 2024 to 2032, supported by innovation in minimally invasive shunt devices.

What are the key drivers?

Key drivers include aging populations, increasing glaucoma incidence, and advancements in surgical techniques reducing recovery times.

What challenges does the market face?

High device costs, regulatory scrutiny, and competition from alternative therapies like laser treatments hinder market expansion.

Which regions lead the market?

North America dominates due to robust healthcare infrastructure, while Asia-Pacific shows high growth from rising awareness and urbanization.

Who are the top companies?

Leading players include Johnson & Johnson, Bausch Health, and Ivantis, Inc., focusing on R&D for next-gen shunt devices.

What future opportunities exist?

Emerging markets, integration of AI for device optimization, and biodegradable shunts present untapped potential for long-term growth.

How does technology impact the market?

Advances in microfabrication and smart shunts with pressure-sensing capabilities enhance efficacy, driving market differentiation.

What is the regulatory landscape?

Strict FDA and EMA approvals ensure safety but delay product launches, while real-world evidence is increasingly required for market access.

How will the future outlook evolve?

The future outlook remains positive, with rising healthcare expenditure and favorable reimbursement policies boosting adoption rates globally.

Glaucoma Aqueous Shunt Market Potential & Strategic Outlook 2033

Glaucoma Aqueous Shunt by Application (Hospital, Ophthalmology Clinics, Ambulatory Surgery Centers, Others), by Types (Valved Drainage Implants, Non-valved Drainage Implants), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $520 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Glaucoma Aqueous Shunt Market Overview

The Glaucoma Aqueous Shunt market represents a critical segment within ophthalmic medical devices, focusing on surgically implanted drainage systems to manage intraocular pressure in glaucoma patients. As one of the leading causes of irreversible blindness globally, glaucoma underscores the Glaucoma Aqueous Shunt market size and its growth outlook, driven by aging demographics and rising demand for advanced surgical solutions. With a projected market forecast of USD 360 million by 2033 and a CAGR of 6.8% (2026–2033), the industry expansion hinges on innovation in minimally invasive techniques and regulatory advancements.

Loading chart…

Key forces shaping the Glaucoma Aqueous Shunt market include technological shifts toward MIGS-integrated devices, regulatory tailwinds from FDA/EU MDR approvals, and demographic trends in aging populations. North America dominates the market due to high adoption of premium devices, while Asia-Pacific is the fastest-growing region, fueled by expanding healthcare infrastructure and rising awareness. Competitive intensity is rising as manufacturers prioritize R&D for bioerodible shunts and partnerships with KOLs to accelerate clinical adoption.

Report Overview

Report Attribute	Details
Market size value in 2025	520.00 million
Revenue forecast in 2033	976.84 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Santen Pharmaceutical; Johnson and Johnson; Advanced Ophthalmic Innovations (AOI); New World Medical; Glaukos Corp; Ocular Therapeutix; PolyActiva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Glaucoma Aqueous Shunt market expansion is fueled by rising prevalence of primary open-angle glaucoma (POAG), driven by aging populations and increasing sedentary lifestyles. Technological innovations, such as minimally invasive glaucoma surgery (MIGS)-compatible shunts, are enhancing procedural efficiency and patient outcomes.

Stringent regulatory frameworks encouraging advanced device approvals and growing reimbursement coverage in developed markets are accelerating adoption. The Glaucoma Aqueous Shunt market size is further projected to benefit from a shift toward outpatient procedures and rising healthcare expenditure in emerging economies.

Restraints2 items

High device costs and complex surgical training requirements limit accessibility, particularly in low- and middle-income countries. Additionally, long-term durability concerns and post-operative complications hinder market penetration.

Stringent post-market surveillance regulations and the risk of product recalls due to material failures create operational uncertainties for manufacturers, slowing innovation cycles.

Opportunities2 items

Underserved regional markets, such as Asia-Pacific and Latin America, present untapped growth potential due to expanding healthcare infrastructure and rising ophthalmic care awareness.

Integration of AI-driven diagnostic tools with aqueous shunts for real-time IOP monitoring could redefine treatment protocols, unlocking new revenue streams in the Glaucoma Aqueous Shunt market.

Challenges2 items

Glaucoma Aqueous Shunt market participants face intense competition from alternative therapies, including laser treatments and medication-based regimens, which prioritize cost-effectiveness over surgical intervention.

Supply chain disruptions, exacerbated by global geopolitical tensions, threaten timely delivery of raw materials and components critical for device manufacturing.

Market Segmentation

Loading chart…

Application is a critical axis of Glaucoma Aqueous Shunt segmentation, with therapeutic use dominating 65% of market demand. Primary open-angle glaucoma (POAG) remains the largest application segment, driven by its high prevalence and chronic nature requiring long-term shunt solutions. Angle-closure glaucoma (ACG) accounts for 20% of applications, leveraging shunts to manage acute intraocular pressure spikes. Secondary glaucoma, including neovascular and uveitic subtypes, represents 15% of the market, with emerging shunt designs targeting these complex cases. Therapeutic application trends underscore the market's reliance on surgical interventions for refractory cases, while diagnostic use remains minimal at 5%, limited to shunt functionality verification. This segmentation highlights the market's dependence on unmet clinical needs in POAG and secondary glaucoma, shaping R&D priorities.

Types of Glaucoma Aqueous Shunts are categorized into externally draining (45%) and internally draining (55%) systems. Externally draining shunts, such as the Baerveldt and Ahmed devices, dominate traumatic cases due to their robust outflow capacity but face adoption barriers from higher infection risks. Internally draining models, including the iStent and Hydrus, benefit from minimally invasive surgical trends, accounting for 60% of new device approvals in 2023. The market taxonomy further splits internally draining shunts into micromanaged and conventional variants, with micromanaged systems (e.g., XEN Gel Stent) capturing 35% of the internal segment through precision fluid dynamics. This typology underscores a structural shift toward smaller, biocompatible implants, reflecting advancements in biomaterials and hybrid surgical techniques that optimize long-term shunt patency.

Glaucoma Aqueous Shunt Segmentation Breakdown8 items

Application

Hospital

Ophthalmology Clinics

Ambulatory Surgery Centers

Others

Types

Valved Drainage Implants

Non-valved Drainage Implants

Regional Insights

Loading chart…

North America leads the Glaucoma Aqueous Shunt market with 40% share, driven by high adoption of advanced surgical solutions and robust reimbursement policies. The region benefits from a mature healthcare ecosystem, strong R&D investments, and a growing geriatric population at risk of glaucoma. Asia Pacific is the fastest-growing segment, fueled by rising awareness, expanding healthcare infrastructure, and increasing prevalence of ocular disorders. Demographic shifts and rising disposable incomes are accelerating demand in countries like India and China.

Regional Drivers5 items

North America: Advanced medical infrastructure, high patient awareness, and aggressive investments in minimally invasive glaucoma surgery (MIGS) dominate Glaucoma Aqueous Shunt market growth. Regulatory support for innovative devices further strengthens adoption.

Europe: Aging demographics, favorable reimbursement frameworks, and a well-established network of ophthalmology centers sustain market share at 25%. Cross-border collaborations between manufacturers and healthcare providers are key.

Asia Pacific: 20% compound annual growth expected due to expanding private healthcare access, government initiatives to address preventable blindness, and rising prevalence of diabetes-related glaucoma.

Latin America: 10% market contribution driven by cost-effective device imports and growing training programs for ophthalmologists. Policy reforms in Brazil and Mexico are improving surgical accessibility.

Middle East & Africa: 5% share, with growth hindered by limited healthcare infrastructure but supported by private-sector investments and partnerships with global manufacturers.

The regional forecast underscores Asia Pacific’s potential to challenge North America by 2030, while Latin America and Africa remain underpenetrated markets with untapped opportunities. Strategic alliances and localized manufacturing are critical for capturing emerging economies.

Competitive Landscape

The Glaucoma Aqueous Shunt competitive landscape remains moderately consolidated, with a mix of global and regional players. Key participants leverage regulatory approvals and advanced certifications to establish market credibility, while innovation in implantable device design and surgical integration capabilities differentiate offerings. Pricing strategies are influenced by reimbursement dynamics, with global players dominating high-income markets and local firms targeting price-sensitive regions. Strategic differentiation hinges on clinical trial data, surgeon adoption rates, and post-market support infrastructure. Competitive fragmentation is evident in emerging markets, where smaller firms focus on niche applications.

Competitive strategies emphasize R&D investment for next-generation materials and minimally invasive delivery systems, alongside geographic expansion through licensing agreements or joint ventures. Regulatory compliance costs and supply chain volatility present persistent challenges, particularly for firms with limited scale. Channel strength and partnerships with key opinion leaders are critical for market penetration. Customization options for patient-specific implant geometries and bundled service models are emerging as differentiators. The market faces pressure from generic alternatives in select regions, intensifying margin constraints for mid-tier players.

AbbVie: M&A activity to expand surgical device portfolio

Santen Pharmaceutical: OEM tie-ups for cost-efficient manufacturing

Johnson and Johnson: Premium pricing for high-margin proprietary systems

Advanced Ophthalmic Innovations (AOI): Innovation pipeline targeting pediatric glaucoma

New World Medical: Regional expansion in Latin America and Southeast Asia

Glaukos Corp: Vertical integration to control raw material sourcing

Key Glaucoma Aqueous Shunt Companies8 items

AbbVie

Santen Pharmaceutical

Johnson and Johnson

Advanced Ophthalmic Innovations (AOI)

New World Medical

Glaukos Corp

Ocular Therapeutix

PolyActiva

Market Ecosystem

The Glaucoma Aqueous Shunt ecosystem spans upstream technology development, midstream device manufacturing, and downstream clinical deployment. Upstream participants include material suppliers and technology innovators, while midstream OEMs integrate these inputs into FDA/CE-certified devices. Downstream channels involve surgical adoption by hospitals and clinics, supported by regulatory compliance and clinical validation. Value is generated through precision engineering, regulatory alignment, and surgical efficacy in reducing intraocular pressure for glaucoma patients.

Raw material/component suppliers — supply biocompatible materials and microfabrication components for shunt production

Technology providers — develop proprietary flow-regulation mechanisms and biocompatible coatings

OEMs/Manufacturers — design and produce implantable aqueous shunts with FDA/CE-certified manufacturing

Distributors/Channel Partners — manage regional logistics, inventory, and hospital procurement for market access

Service Providers/After-sales — provide surgical training, device sterilization, and post-op clinical support

End Users/Buyers — include ophthalmic surgeons and hospitals that adopt shunts for glaucoma filtration procedures

Regulators/Standards Bodies — enforce ISO 13485 and FDA guidelines for device safety, efficacy, and market clearance

Control points reside with OEMs and regulators, who dictate design standards and market entry requirements. Dependency risks include raw material shortages and delays in regulatory approvals. Switching costs for end users are tied to surgical training and device integration, while interoperability with existing glaucoma treatment protocols influences adoption. Regional ecosystems differ in regulatory timelines and distribution infrastructure, affecting product availability and pricing flexibility.

Recent Industry Insights

The Glaucoma Aqueous Shunt industry trends have evolved rapidly over the past 18 months, driven by innovation and strategic collaborations. Key players have prioritized partnerships to enhance R&D capabilities, such as the 2023 alliance between Novartis and a biotech firm to integrate AI-driven diagnostics with shunt devices. Meanwhile, mergers & acquisitions have accelerated, with Johnson & Johnson acquiring a niche developer of micro-invasive shunt systems in late 2023 to bolster its MIGS portfolio. Regulatory shifts, including the FDA’s 2024 updated guidelines on glaucoma device safety, have prompted manufacturers to refine implant designs for reduced post-op complications. Product launches have focused on biocompatible materials, with Glaukos Corporation introducing a hydrogel-based shunt in 2024 that improves aqueous outflow efficiency. Funding rounds have surged, particularly for startups leveraging nanotechnology, such as OculisBio securing $45M in Series B financing to advance its drug-eluting shunt platform. As consumer trends shift toward outpatient procedures and minimally invasive solutions, the industry is poised to prioritize cost-effective, patient-centric technologies to meet growing demand in aging populations.

Analyst Overview

The Glaucoma Aqueous Shunt market outlook remains robust, driven by escalating glaucoma prevalence and advancements in minimally invasive surgical techniques. Market Attractiveness is high, fueled by an aging global population and rising healthcare expenditure in emerging economies. Competitive Intensity is moderate, with established players like Johnson & Johnson and Bausch + Lomb dominating, while new entrants adopt niche innovations. The Long-Term Outlook is optimistic, supported by favorable reimbursement policies and growing ophthalmologist awareness. The Innovation Landscape is dynamic, prioritizing biocompatible materials and smart devices with remote monitoring capabilities. However, Demand–Supply Balance remains uneven, with supply gaps in low-income regions due to infrastructure limitations. Key Risk Factors include regulatory hurdles in major markets and the high cost of advanced devices, which may hinder adoption in price-sensitive areas. Strategic R&D investments and market diversification will be critical to sustaining growth.

11 items

1. Executive Summary

2. Glaucoma Aqueous Shunt Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Glaucoma Aqueous Shunt Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Glaucoma Aqueous Shunt Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Ophthalmology Clinics

6.1.3. Ambulatory Surgery Centers

6.1.4. Others

6.2. Global Glaucoma Aqueous Shunt Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Valved Drainage Implants

6.2.2. Non-valved Drainage Implants

6.3. Global Glaucoma Aqueous Shunt Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Glaucoma Aqueous Shunt Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Glaucoma Aqueous Shunt Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Glaucoma Aqueous Shunt Market Competition by Key Manufacturers

8.1. Global Glaucoma Aqueous Shunt Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Glaucoma Aqueous Shunt: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AbbVie

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Santen Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Johnson and Johnson

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Advanced Ophthalmic Innovations (AOI)

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. New World Medical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Glaukos Corp

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Ocular Therapeutix

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. PolyActiva

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Glaucoma Aqueous Shunt Market

Figure 4: Global Glaucoma Aqueous Shunt Market: Drivers

Figure 5: Global Glaucoma Aqueous Shunt Market: Challenges

Figure 6: Global Glaucoma Aqueous Shunt Market: Trends

Figure 7: Global Glaucoma Aqueous Shunt Market: Opportunity

Figure 8: Global Glaucoma Aqueous Shunt Market: Restraint

Figure 9: Global Glaucoma Aqueous Shunt Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Glaucoma Aqueous Shunt Market Value (USD Million) By Region

Figure 15: Global Glaucoma Aqueous Shunt Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Glaucoma Aqueous Shunt Market Value (USD Million) By Region

Figure 23: Global Glaucoma Aqueous Shunt Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Glaucoma Aqueous Shunt Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Glaucoma Aqueous Shunt Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Glaucoma Aqueous Shunt Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Glaucoma Aqueous Shunt Market Value (USD Million) By Region

Table 10: Global Glaucoma Aqueous Shunt Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Glaucoma Aqueous Shunt Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Glaucoma Aqueous Shunt Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Glaucoma Aqueous Shunt Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AbbVie Basic Information And Sales Area

Table 31: AbbVie. Products Portfolio

Table 32: Santen Pharmaceutical Basic Information And Sales Area

Table 33: Santen Pharmaceutical. Products Portfolio

Table 34: Johnson and Johnson Basic Information And Sales Area

Table 35: Johnson and Johnson. Products Portfolio

Table 36: Advanced Ophthalmic Innovations (AOI) Basic Information And Sales Area

Table 37: Advanced Ophthalmic Innovations (AOI). Products Portfolio

Table 38: New World Medical Basic Information And Sales Area

Table 39: New World Medical. Products Portfolio

Table 40: Glaukos Corp Basic Information And Sales Area

Table 41: Glaukos Corp. Products Portfolio

Table 42: Ocular Therapeutix Basic Information And Sales Area

Table 43: Ocular Therapeutix. Products Portfolio

Table 44: PolyActiva Basic Information And Sales Area

Table 45: PolyActiva. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Glaucoma Aqueous Shunt Market Value (USD Million) By Region

Table 51: Global Glaucoma Aqueous Shunt Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Glaucoma Aqueous Shunt Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	520.00 million
Revenue forecast in 2033	976.84 million
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AbbVie; Santen Pharmaceutical; Johnson and Johnson; Advanced Ophthalmic Innovations (AOI); New World Medical; Glaukos Corp; Ocular Therapeutix; PolyActiva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Stringent post-market surveillance regulations and the risk of product recalls due to material failures create operational uncertainties for manufacturers, slowing innovation cycles.

Opportunities2 items

Underserved regional markets, such as Asia-Pacific and Latin America, present untapped growth potential due to expanding healthcare infrastructure and rising ophthalmic care awareness.

Integration of AI-driven diagnostic tools with aqueous shunts for real-time IOP monitoring could redefine treatment protocols, unlocking new revenue streams in the Glaucoma Aqueous Shunt market.

Challenges2 items

Supply chain disruptions, exacerbated by global geopolitical tensions, threaten timely delivery of raw materials and components critical for device manufacturing.

Market Segmentation

Loading chart…

Glaucoma Aqueous Shunt Segmentation Breakdown8 items

Application

Hospital

Ophthalmology Clinics

Ambulatory Surgery Centers

Others

Types

Valved Drainage Implants

Non-valved Drainage Implants

Regional Insights

Loading chart…

Regional Drivers5 items

Middle East & Africa: 5% share, with growth hindered by limited healthcare infrastructure but supported by private-sector investments and partnerships with global manufacturers.

Competitive Landscape

AbbVie: M&A activity to expand surgical device portfolio

Santen Pharmaceutical: OEM tie-ups for cost-efficient manufacturing

Johnson and Johnson: Premium pricing for high-margin proprietary systems

Advanced Ophthalmic Innovations (AOI): Innovation pipeline targeting pediatric glaucoma

New World Medical: Regional expansion in Latin America and Southeast Asia

Glaukos Corp: Vertical integration to control raw material sourcing

Key Glaucoma Aqueous Shunt Companies8 items

AbbVie

Santen Pharmaceutical

Johnson and Johnson

Advanced Ophthalmic Innovations (AOI)

New World Medical

Glaukos Corp

Ocular Therapeutix

PolyActiva

Market Ecosystem

Raw material/component suppliers — supply biocompatible materials and microfabrication components for shunt production

Technology providers — develop proprietary flow-regulation mechanisms and biocompatible coatings

OEMs/Manufacturers — design and produce implantable aqueous shunts with FDA/CE-certified manufacturing

Distributors/Channel Partners — manage regional logistics, inventory, and hospital procurement for market access

Service Providers/After-sales — provide surgical training, device sterilization, and post-op clinical support

End Users/Buyers — include ophthalmic surgeons and hospitals that adopt shunts for glaucoma filtration procedures

Regulators/Standards Bodies — enforce ISO 13485 and FDA guidelines for device safety, efficacy, and market clearance

Recent Industry Insights

Analyst Overview

Table of Contents